Incyte Co. (INCY) EVP Sells $732,100.00 in Stock

Share on StockTwits

Incyte Co. (NASDAQ:INCY) EVP Paula J. Swain sold 10,000 shares of the firm’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $73.21, for a total value of $732,100.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

NASDAQ:INCY traded down $3.08 during trading hours on Friday, hitting $69.13. The company’s stock had a trading volume of 58,533 shares, compared to its average volume of 1,284,077. The firm has a market capitalization of $15.78 billion, a PE ratio of 108.77 and a beta of 1.14. The company has a quick ratio of 4.32, a current ratio of 4.34 and a debt-to-equity ratio of 0.01. Incyte Co. has a twelve month low of $60.22 and a twelve month high of $137.35.

Incyte (NASDAQ:INCY) last released its quarterly earnings data on Tuesday, July 31st. The biopharmaceutical company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.22. The business had revenue of $521.50 million for the quarter, compared to analyst estimates of $510.70 million. Incyte had a positive return on equity of 1.74% and a negative net margin of 5.92%. Incyte’s revenue was up 59.8% compared to the same quarter last year. During the same period last year, the firm posted ($0.06) earnings per share. analysts anticipate that Incyte Co. will post 0.43 EPS for the current fiscal year.

Large investors have recently added to or reduced their stakes in the stock. Global X Management Co. LLC boosted its stake in shares of Incyte by 13.1% during the first quarter. Global X Management Co. LLC now owns 13,234 shares of the biopharmaceutical company’s stock valued at $1,103,000 after purchasing an additional 1,528 shares in the last quarter. Daiwa Securities Group Inc. boosted its stake in shares of Incyte by 36.8% during the first quarter. Daiwa Securities Group Inc. now owns 7,107 shares of the biopharmaceutical company’s stock valued at $592,000 after purchasing an additional 1,911 shares in the last quarter. Dupont Capital Management Corp acquired a new stake in shares of Incyte during the first quarter valued at about $1,683,000. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of Incyte by 1.5% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 507,195 shares of the biopharmaceutical company’s stock valued at $42,265,000 after purchasing an additional 7,612 shares in the last quarter. Finally, Zeke Capital Advisors LLC acquired a new stake in shares of Incyte during the first quarter valued at about $421,000. 91.53% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts recently commented on the company. Cowen restated a “buy” rating on shares of Incyte in a research report on Tuesday. BidaskClub upgraded Incyte from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 31st. Argus set a $83.00 price target on Incyte and gave the stock a “buy” rating in a research report on Thursday, August 30th. Royal Bank of Canada upgraded Incyte from a “sector perform” rating to an “outperform” rating and set a $74.00 price target on the stock in a research report on Wednesday, August 15th. They noted that the move was a valuation call. Finally, JMP Securities cut Incyte from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 1st. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. Incyte currently has an average rating of “Buy” and an average target price of $100.51.

About Incyte

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Featured Article: Momentum Indicator: Relative Strength Index

Insider Buying and Selling by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply